Company intelligence / Profile preview
Dragonfly Therapeutics
Waltham/Boston area*, MA, USAdragonflytx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 2
01
Overview
Dragonfly Therapeutics has reported encouraging early clinical results for its lead TriNKET® programs. DF1001 targeting HER2 showed pharmacodynamic responses in two-thirds of patients with advanced solid tumors in a Phase 1 trial, with signs of clinical benefit and a favorable safety profile. DF9001 targeting EGFR has entered combination trials with Merck’s KEYTRUDA®, aiming to expand efficacy in EGFR-positive cancers. The company’s platforms have enabled a broad pipeline spanning oncology and autoimmune indications.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Multispecific antibodies (TriNKET® platform)Engineered cytokines (CYTOKINE platform)Protein drugsAntibodiesTrispecific killer cell engagers (TriKE)
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
Bristol Myers Squibb/BMS [collaboration/licensing on immuno-oncology assets].Merck/MSD [collaboration on DF9001 + KEYTRUDA].AbbVie [immunology collaboration].Gilead Sciences [immunotherapy collaboration].
Beyond the preview
Go deeper on Dragonfly Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dragonfly Therapeutics.